球体物质在制备静脉注射剂中的应用
By using MSC spheres or similarly sized biomaterial spheres for intravenous injection, the problems of rapid MSC clearance and pulmonary retention have been solved, achieving longer-lasting efficacy and a safer route of administration, making it suitable for the diagnosis and treatment of a variety of diseases.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- UNIV OF MACAU
- Filing Date
- 2022-03-17
- Publication Date
- 2026-07-17
AI Technical Summary
Intravenously injected mesenchymal stromal cells (MSCs) are rapidly cleared in the body, leading to unstable efficacy. Furthermore, existing intravenous MSC injection protocols suffer from pulmonary retention and potential adverse reactions, limiting their clinical application.
Intravenous injection of spherical materials, such as mesenchymal stem cell (MSC) spheres or biomaterials of similar size, can reduce pulmonary retention, prolong the retention time in the blood and peripheral tissues, and carry drugs or bioactive molecules for treatment.
Intravenous injection of MSCs reduces pulmonary retention, improves efficacy, provides a safe route of administration, and can carry multiple molecules to produce synergistic effects, making it suitable for the diagnosis and treatment of a variety of diseases.
Smart Images
Figure CN115590883B_ABST